|
For immediate release |
3 October 2013 |
RNS REACH
Futura Medical plc("Futura" or the "Company")
Equity Research Service
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that an equity research service has been added to the investor section of Futura's website and that an initiation of coverage report can be viewed at this link: www.futuramedical.com/archive/research/FuturaMedical021013outlook.pdf
Shareholders or potential shareholders will automatically be notified of any future research reports if they register with the Company's investor alert service at the following link: www.futuramedical.com/content/investors/alert_service.asp
For any further information please contact:
|
Futura Medical plc |
|
|
James Barder, Chief Executive |
Tel: +44 (0)1483 685 670 |
|
mail to: james.barder@futuramedical.com |
|
|
Cenkos Securities plc |
|
|
Bobbie Hilliam |
Tel:+44 (0)20 7397 8900 |
|
For media enquiries please contact: |
|
|
Buchanan |
|
|
Mark Court / Fiona Henson / Sophie Cowles |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
This information is provided by RNS